1月29日，随着全国大中小学陆续进入寒假，视力检查与近视防控需求迎来年度高峰。腾讯健康与全球 光学行业领导者蔡司光学宣布达成战略合作，正式推出"少儿护眼Dr.Z"智能体。 此次合作的落地，也反映出AI与医疗行业深度融合的全新趋势。对于腾讯云而言，这是其在持续加大 AI战略投入背景下，将大模型能力从通用场景向眼科垂直专科场景落地的具体实践，标志着腾讯健康 业务正逐步从基础设施搭建转向垂直场景的智能化应用。而对于蔡司光学而言，这标志着其"创新在中 国，推广到世界"理念的进一步深化。作为全球光学与眼健康领域的领导者，蔡司光学通过此次合作， 创新性地将全球顶尖的视光技术积淀与腾讯云领先的AI数字生态深度融合，探索出一条跨国企业在华 数字化转型的示范路径。 家长上传眼健康检查报告单后，智能体不仅能解读数据，还能关联多维度指标进行深度分析。例如，当 系统检测到孩子眼健康报告结果异常时，系统会提示相关风险，并解释因果及给出相应的干预建议，实 现了从"告知数据"到"解释因果"的跨越。 从行业需求端来看，这一产品的推出也契合了当前"关口前移"的防控趋势。据了解，目前青少年近视防 控已上升为国家战略，相关部门多次发文要求建立儿童 ...

Core Viewpoint - Ark Health Holdings Limited announced the resignation of Mr. Xie Fangmin as Chairman, CEO, and authorized representative effective December 7, 2025, to focus on personal matters, while he will continue to provide guidance as a non-executive director [1][2] Group 1: Leadership Changes - Mr. David McKee Hand has been appointed as the new Chairman effective December 7, 2025, following Mr. Xie Fangmin's resignation [1] - The board has initiated a formal search for a new CEO, considering both internal and external candidates to ensure a suitable successor [1] Group 2: Contributions and Future Direction - Mr. Xie Fangmin has been instrumental in the company's long-term development since its founding in 2015, introducing the "H2H (Hospital to Home)" model and integrating AI with healthcare [2] - Under his leadership, the company transitioned from a pharmaceutical e-commerce platform to a leading "AI + chronic disease management" enterprise, successfully listing on the Hong Kong Stock Exchange in 2024 [2] - The company aims to continue focusing on online chronic disease management, leveraging AI to serve millions of patients and contribute to the "Healthy China 2030" initiative [2]

Core Viewpoint - Ark Health Holdings Limited announced the resignation of Mr. Xie Fangmin as Chairman, CEO, and other positions effective December 7, 2025, to focus on personal matters, while he will continue to provide guidance as a non-executive director [1][2] Group 1: Leadership Changes - Mr. Xie Fangmin's resignation is respected by the board, which appreciates his significant contributions during his tenure [1] - David McKee Hand has been appointed as the new Chairman effective December 7, 2025, while the board will search for a new CEO from both internal and external candidates [1] Group 2: Company Strategy and Future Direction - Since its establishment in 2015, Mr. Xie has focused on the long-term development of the company, introducing the "H2H (Hospital to Home)" model and integrating AI with healthcare [2] - The company has transitioned from a pharmaceutical e-commerce platform to a leading "AI + chronic disease management" enterprise, successfully listing on the Hong Kong Stock Exchange in 2024 [2] - The company aims to continue focusing on online chronic disease management and building a win-win ecosystem for chronic disease services, contributing to the "Healthy China 2030" goal [2]